Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors: results from the DeFi trial : clinical trial updates
In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PRO) in adult patients with progr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 20, 2025
|
| In: |
Journal of clinical oncology
Year: 2025, Volume: 43, Issue: 34, Pages: 3646-3651 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO-25-00582 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1200/JCO-25-00582 Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/10.1200/JCO-25-00582 
|
| Author Notes: | Ravin Ratan, MD, ME, Bernd Kasper, MD, PhD, Thierry Alcindor, MD, MS, Patrick Schöffski, MD, Winette T.A. van der Graaf, MD, PhD, Noah Federman, MD, Nam Q. Bui, MD, Gina D’Amato, MD, Richard F. Riedel, MD, Steven Attia, DO, Sant Chawla, MD, Allison Lim, PharmD, Brad Tumminello, PharmD, Ana B. Oton, MD, Yucheng Chu, MS, Shengfan Zhou, MS, and Mrinal Gounder, MD |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949990311 | ||
| 003 | DE-627 | ||
| 005 | 20260122104413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260122s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO-25-00582 |2 doi | |
| 035 | |a (DE-627)1949990311 | ||
| 035 | |a (DE-599)KXP1949990311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ratan, Ravin |e VerfasserIn |0 (DE-588)1387656147 |0 (DE-627)1949991008 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors |b results from the DeFi trial : clinical trial updates |c Ravin Ratan, MD, ME, Bernd Kasper, MD, PhD, Thierry Alcindor, MD, MS, Patrick Schöffski, MD, Winette T.A. van der Graaf, MD, PhD, Noah Federman, MD, Nam Q. Bui, MD, Gina D’Amato, MD, Richard F. Riedel, MD, Steven Attia, DO, Sant Chawla, MD, Allison Lim, PharmD, Brad Tumminello, PharmD, Ana B. Oton, MD, Yucheng Chu, MS, Shengfan Zhou, MS, and Mrinal Gounder, MD |
| 264 | 1 | |c October 20, 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.01.2026 | ||
| 520 | |a In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PRO) in adult patients with progressing desmoid tumors (DT; median [range] exposure: 20.6 [0.3-33.6] months). Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024. End points included PFS and ORR per RECIST v1.1, PRO, and safety. The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis. Further target tumor size reduction occurred in most patients. Benefits in PROs were sustained while on treatment. Frequently reported treatment-emergent adverse events (TEAEs) decreased in incidence and severity over time. Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4. In conclusion, long-term continuous nirogacestat treatment was associated with further tumor size reductions, durable objective responses, sustained PRO benefits, and a manageable safety profile consistent with the primary analysis. | ||
| 700 | 1 | |a Kasper, Bernd |d 1974- |e VerfasserIn |0 (DE-588)12274764X |0 (DE-627)082130736 |0 (DE-576)29340447X |4 aut | |
| 700 | 1 | |a Alcindor, Thierry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schöffski, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a van der Graaf, Winette T.A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Federman, Noah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bui, Nam Q. |e VerfasserIn |4 aut | |
| 700 | 1 | |a D'Amato, Gina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Riedel, Richard F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Attia, Steven |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chawla, Sant |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lim, Allison |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tumminello, Brad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oton, Ana B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chu, Yucheng |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhou, Shengfan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gounder, Mrinal |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 43(2025), 34, Seite 3646-3651 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors results from the DeFi trial : clinical trial updates |
| 773 | 1 | 8 | |g volume:43 |g year:2025 |g number:34 |g pages:3646-3651 |g extent:8 |a Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors results from the DeFi trial : clinical trial updates |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO-25-00582 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO-25-00582 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260122 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 12274764X |a Kasper, Bernd |m 12274764X:Kasper, Bernd |d 60000 |d 61200 |e 60000PK12274764X |e 61200PK12274764X |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 999 | |a KXP-PPN1949990311 |e 4857438313 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors","subtitle":"results from the DeFi trial : clinical trial updates","title_sort":"Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors"}],"language":["eng"],"id":{"eki":["1949990311"],"doi":["10.1200/JCO-25-00582"]},"physDesc":[{"noteIll":"Diagramme","extent":"8 S."}],"note":["Gesehen am 22.01.2026"],"relHost":[{"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"id":{"zdb":["2005181-5"],"issn":["1527-7755"],"eki":["313116962"]},"disp":"Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors results from the DeFi trial : clinical trial updatesJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"recId":"313116962","origin":[{"dateIssuedKey":"1983","dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"pubHistory":["1.1983 -"],"part":{"text":"43(2025), 34, Seite 3646-3651","year":"2025","volume":"43","issue":"34","pages":"3646-3651","extent":"8"},"language":["eng"],"title":[{"title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1949990311","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"October 20, 2025"}],"person":[{"display":"Ratan, Ravin","role":"aut","given":"Ravin","family":"Ratan"},{"family":"Kasper","display":"Kasper, Bernd","role":"aut","given":"Bernd"},{"display":"Alcindor, Thierry","given":"Thierry","role":"aut","family":"Alcindor"},{"family":"Schöffski","display":"Schöffski, Patrick","role":"aut","given":"Patrick"},{"family":"van der Graaf","given":"Winette T.A.","role":"aut","display":"van der Graaf, Winette T.A."},{"family":"Federman","display":"Federman, Noah","role":"aut","given":"Noah"},{"display":"Bui, Nam Q.","role":"aut","given":"Nam Q.","family":"Bui"},{"family":"D'Amato","display":"D'Amato, Gina","given":"Gina","role":"aut"},{"family":"Riedel","role":"aut","given":"Richard F.","display":"Riedel, Richard F."},{"display":"Attia, Steven","role":"aut","given":"Steven","family":"Attia"},{"display":"Chawla, Sant","given":"Sant","role":"aut","family":"Chawla"},{"family":"Lim","role":"aut","given":"Allison","display":"Lim, Allison"},{"family":"Tumminello","display":"Tumminello, Brad","given":"Brad","role":"aut"},{"role":"aut","given":"Ana B.","display":"Oton, Ana B.","family":"Oton"},{"family":"Chu","display":"Chu, Yucheng","given":"Yucheng","role":"aut"},{"given":"Shengfan","role":"aut","display":"Zhou, Shengfan","family":"Zhou"},{"family":"Gounder","display":"Gounder, Mrinal","role":"aut","given":"Mrinal"}],"name":{"displayForm":["Ravin Ratan, MD, ME, Bernd Kasper, MD, PhD, Thierry Alcindor, MD, MS, Patrick Schöffski, MD, Winette T.A. van der Graaf, MD, PhD, Noah Federman, MD, Nam Q. Bui, MD, Gina D’Amato, MD, Richard F. Riedel, MD, Steven Attia, DO, Sant Chawla, MD, Allison Lim, PharmD, Brad Tumminello, PharmD, Ana B. Oton, MD, Yucheng Chu, MS, Shengfan Zhou, MS, and Mrinal Gounder, MD"]}} | ||
| SRT | |a RATANRAVINEFFICACYAN2020 | ||